Navigation Links
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Date:3/9/2010

ements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the continued analyses of clinical trial results, including Contrave Phase 3 trials; the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave and Empatic; reliance on third parties to assist with the development of Contrave and Empatic and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave or Empatic; the potential to enter into and the terms of any commercial partnership or other strategic transaction relating to Contrave or Empatic; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    
    
                          Orexigen Therapeutics, Inc.                         
                         (a development stage company)                        
                            Statements of Operations                          
                    (In thousands, except per share amounts)                  
                                  (Unaudited)                                 
                                                                              
                                                                  Period from 
      
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014 ... in Tokio veranstalteten ... firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. Die ... Überblick über die fortgeschrittenen klinischen Programme und ... Ziel der Tagung bestand darin, aktuelle Meldungen ...
(Date:7/13/2014)... 13, 2014  Eli Lilly and Company (NYSE: ... its non-clinical study in genetically engineered mice examining ... beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). ... effective in removing clumps of amyloid-beta protein in ... to lead to Alzheimer,s disease (AD) – than ...
(Date:7/11/2014)... LOS ANGELES , July 11, 2014 /PRNewswire-iReach/ ... of e-liquid, a vegetable-glycol solution for use in ... one of the active ingredients in cannabis, cannabidiol ... in personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... -- Golden Meditech Holdings Limited ("Golden Meditech" or ... today announced that the Group has accumulated 754,791 ordinary shares ... CO.US) from the open market between December 2010 and March ... 39.5% of the issued share capital of CCBC. ...
... Mass., June 23, 2011 SeraCare Life Sciences, Inc. (NASDAQ: ... vital products and services to facilitate the discovery, development and ... of an unsolicited offer from MSMB Capital proposing to purchase ... share. It is anticipated that the SeraCare Board of Directors ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2SeraCare Acknowledges Receipt of Unsolicited Proposal from MSMB Capital 2
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... new type of sensor for people with diabetes is being ... instead of blood, researchers report. Scientists at Brown University ... using artificial saliva. It uses light, metal and a special ... "Everybody knows that diabetics have to prick their fingers to ...
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
(Date:7/13/2014)... ECS is being founded by ... of a special needs child, I have become keenly ... for contemporary special education resources and evidence-based instruction. Emerald ... and families in the Seattle metro area that are ... education. We welcome the opportunity to serve our community ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
... Dr. Gunther von Hagens, creator of the BODY ... to present the human saga in its entirety, introduced ... week.(Photo: http://www.newscom.com/cgi-bin/prnh/20090505/CG11117 )With the "HUMAN SAGA" project, ... landscape left uncharted by Andreas Vesalius (1514-1564), the founder ...
... in Traditional Chinese Medicine Research in the Post-genomic Era, ... Medicine (TCM) research, identify problems and propose solutions by ... a forum for the exchange of opinions, experience and ... , The three-year project aims to propose guidelines ...
... Savings Accounts and Supplemental Coverage for Critical Illnesses and ... Guardian Life Insurance Company of America (Guardian), one of ... leading provider of employee benefits for small and mid-sized ... healthcare plan that helps employers and their employees save ...
... YORK, May 5 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... improving health through the development, manufacture and,commercialization of a ... today announced that it plans to release first quarter ... market opens. , The Company ...
... don,t make it to the doctor , , TUESDAY, May ... a lack of belief in the importance of vaccinations ... to getting parents to bring their children in for ... linked to children being 2.5 times more likely to ...
... Finder Introduces Initiative to Secure Patient Health InformationNEW YORK, ... of the nation,s healthcare system and said he believes ... five years. The President hopes this will result in ... thousands of new jobs. Todd Feinman, a published security ...
Cached Medicine News:Health News:Dr. Gunther von Hagens 'HUMAN SAGA' Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life. 2Health News:King's-led consortium wins €1 million EU funding for Chinese medicine research 2Health News:Guardian Launches Comprehensive, Consumer-Driven Healthcare Program 2Health News:Guardian Launches Comprehensive, Consumer-Driven Healthcare Program 3Health News:Keeping Appointments Key to Keeping Vaccines on Track 2Health News:Obama's Support for Digital Health Records May Increase Identity Theft 2Health News:Obama's Support for Digital Health Records May Increase Identity Theft 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: